Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039003 | 0.82 | MAPT (0.38) | KMT2AMAPTLTA4HMEN1L3MBTL1 | |
| SCHEMBL23670944 | 0.80 | NPC1 (0.43) | TSHRCYP3A4KMT2ALTA4HNPC1 | |
| SCHEMBL11003099 | 0.77 | PLA2G2A (0.50) | TSHRTP53LTA4HNPC1 | |
| SCHEMBL28069071 | 0.76 | NQO1 (0.46) | NQO1TSHRTDP1TP53CYP3A4 | |
| SCHEMBL1683212 | 0.76 | NQO1 (0.65) | NQO1TSHRTDP1TP53CYP3A4 | |
| SCHEMBL3780893 | 0.75 | NQO1 (0.50) | NQO1TSHRTDP1TP53CYP3A4 | |
| SCHEMBL1547677 | 0.75 | MAPT (0.54) | NQO1TSHRTDP1TP53CYP3A4 | |
| SCHEMBL146623 | 0.75 | NQO1 (0.50) | NQO1TSHRTDP1TP53CYP3A4 | |
| SCHEMBL1148347 | 0.74 | NQO1 (0.44) | NQO1TSHRTDP1TP53CYP3A4 | |
| SCHEMBL1636165 | 0.73 | NQO1 (0.48) | NQO1TSHRTDP1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107086-A1 | PROCATALYST FOR OLEFIN POLYMERIZATION AND USE THEREOF | PUBLIC JOINT STOCK COMPANY "SIBUR HOLDING" (PJSC "SIBUR HOLDING") (RU) | 2024-05-23 | — | — | WO | disclosed |
| US-8455511-B2 | Pyrrolopyridine derivatives substituted with cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-20110130364-A1 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-02 | — | — | US | disclosed |
| US-7951811-B2 | Antagonist against corticotropen releasing factor receptors; antidepressants, anxiolytic agents, Alzheimer's disease; Parkinson's disease; eating disorders; hypotensive agents; gastrointestinal disorders; drug abuse; brain disorders; antiischemic agents; antiinflammatory agents; immunotherapy; alopecia | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20110124862-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-7932259-B2 | Pyrrolo[2,3-d]pyrimidine derivatives substituted with a cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| EP-1787992-B1 | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-04-29 | — | — | EP | disclosed |
| US-20080287397-A1 | Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group | TASHO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-20 | — | — | US | disclosed |
| US-20080280928-A1 | Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with a Cyclic Amino Group As Crf Antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-13 | — | — | US | disclosed |
| EP-1467997-B8 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | TAISHO PHARMACEUTICAL CO LTD (JP) | 2008-08-27 | — | — | EP | disclosed |
| US-6476038-B1 | Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines | NEUROGEN CORPORATION | 2002-11-05 | — | — | US | disclosed |
| EP-1218381-A2 | AMINO SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2002-07-03 | — | — | EP | disclosed |
| EP-1218379-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6372743-B1 | EATING DISORDERS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | NEUROGEN CORPORATION | 2002-04-16 | — | — | US | disclosed |
| WO-2001023387-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001023388-A2 | AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-0914354-A1 | POLYMERIZATION PROCESSES FOR OLEFINS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-05-12 | — | — | EP | disclosed |
| WO-1998003559-A1 | POLYMERIZATION PROCESSES FOR OLEFINS | E.I. DU PONT DE NEMOURS AND COMPNAY (US) | 1998-01-29 | — | — | WO | disclosed |
| US-5169958-A | Reacting, 3-amino-2-propen-1-ones with magnesium halide in solvent | BASF AKTIENGESELLSCHAFT (DE) | 1992-12-08 | — | — | US | disclosed |
| EP-0480242-A2 | Method for the production of alpha,beta-unsaturated carbonyl compounds | BASF Aktiengesellschaft (DE) | 1992-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287397-A1 | Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group | HRH2, HRH4, CRHR1 | NQO1 3496/4885TSHR 323/4885TDP1 2392/4885 |
| US-20110130364-A1 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | HRH2, HRH4, CRHR1 | NQO1 3593/4885TSHR 333/4885TDP1 2300/4885 |
| US-20080280928-A1 | Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with a Cyclic Amino Group As Crf Antagonists | CRHR1, CRHR2, HRH4 | NQO1 3774/4885TSHR 375/4885TDP1 2285/4885 |
| US-20110124862-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | CRHR1, HRH2, CRHR2 | NQO1 3756/4885TSHR 335/4885TDP1 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.